The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISHL HL Update 2021 | 1st-line therapies in Hodgkin lymphoma
Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, discusses innovative 1st-line therapies currently being evaluated in patients with Hodgkin lymphoma, the perspective of the German Hodgkin Study Group, including the ongoing HD21 trial (NCT02661503), as well as elderly patients with Hodgkin lymphoma, who represent an area of unmet need. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.
